Results 101 to 110 of about 6,710,280 (212)

Molecular research on drug induced liver injury

, 2018
Drugs may cause liver injury in a few susceptible individuals, but the molecular events that lead to this idiosyncratic, largely dose-independent and non-predictable drug-induced liver injury (DILI) are mostly unknown, since animal models to explore the ...
Rolf Teschke, Danan, Gaby, Gaby Danan, Teschke, Rolf   +3 more
core   +1 more source

Drug‐induced cholestasis

Hepatology Communications, 2017
Cholestatic drug‐induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition.
Vinay Sundaram, Einar S. Björnsson
doaj   +1 more source

Mechanistic insights into antiretroviral drug‐induced liver injury

Pharmacology Research & Perspectives, 2020
All classes of antiretroviral therapy (ART) have been implicated to induce adverse drug reactions such drug‐induced liver injury (DILI) and immune‐mediated adverse reactions in Human Immunodeficiency Virus (HIV) infected individuals.
Jamie N. Pillaye, Mohlopheni J. Marakalala, Nonhlanhla Khumalo, Wendy Spearman, Hlumani Ndlovu   +4 more
doaj   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3874-3885, November 2026.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem, Mohannad N. AbuHaweeleh, Humam Emad Rajha, Mhd Osama Rahhal, Ahmad Hamdan, Lina Naseralallah   +5 more
wiley   +1 more source

Prediction of Acute Liver Injury Trajectory in Patients Following Acetaminophen Overdose: A Multibiomarker Machine Learning Proof‐of‐Concept Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1326-1337, November 2026.
Clinical translation of novel therapies can be hindered by heterogeneity‐driven sample size inflation in late‐stage trials. In acetaminophen‐induced liver injury (APAP DILI), many patients recover spontaneously, diluting investigational drug efficacy signals.
Chris Humphries, Alastair M. Kilpatrick, Kathleen M. Scullion, Rhona Aird, Lorraine Bruce, Maria Elena Candela, Tak Yung Man, Stuart J. Forbes, James W. Dear   +8 more
wiley   +1 more source

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1358-1367, November 2026.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer   +4 more
wiley   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

Clinical factors predicting drug-induced liver injury due to flucloxacillin

, 2018
Mikaela Lindh,1 Pär Hallberg,1 Qun-Ying Yue,2 Mia Wadelius1 1Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden; 2Swedish Medical Products Agency, Uppsala, Sweden Objectives ...
Lindh M, Yue QY, Hallberg P, Wadelius M
core  

Role of Gut Microecology in the Pathogenesis of Drug-Induced Liver Injury and Emerging Therapeutic Strategies

Molecules
Drug-induced liver injury (DILI) is a common clinical pharmacogenic disease. In the United States and Europe, DILI is the most common cause of acute liver failure.
Yuqiao Huang, Yu Zhang, Kaireng Wu, Xinxin Tan, Tian Lan, Guixiang Wang   +5 more
doaj   +1 more source

Drug-induced liver injury. Part II: Late complications and hepatotoxicity monitoring

The picture of drug-induced liver injury (DILI) is polymorphic, with variable intensity of clinical symptoms and prognosis. Most cases of DILI are acute, although the incidence of chronic hepatopathy has been reported to range from 3.4% to 39.0% in the ...
Dorota M. Kozielewicz, Piotr Stalke
core   +1 more source